Close Menu

NEW YORK -- UK-based molecular diagnostics firm Yourgene Health said on Monday its Elucigene DPYD test is now being offered to all patients undergoing chemotherapy in Wales.

Wales implemented a screening program to routinely test all patients undergoing chemotherapy with the Elucigene DPYD test. The screening identifies patients with ihydropyrimidine dehydrogenase (DPD) deficiency, which can lead to severe side effects in patients being treated with chemotherapeutic drug 5-fluorouracil.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.